<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This report describes the response of 18 Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) patients to recombinant human interleukin 3 (rhIL-3) </plain></SENT>
<SENT sid="1" pm="."><plain>rhIL-3 was administered s.c. once daily on an escalating dose schedule (0.5-10 micrograms/kg/day) </plain></SENT>
<SENT sid="2" pm="."><plain>The rhIL-3 dose was escalated every 21 days until erythroid response was attained, grade III or IV nonhematologic toxicity was observed, or the maximal rhIL-3 dose was reached </plain></SENT>
<SENT sid="3" pm="."><plain>Four patients experienced clinically significant erythroid responses </plain></SENT>
<SENT sid="4" pm="."><plain>Two of the responders were steroid-dependent and transfusion-independent, while two were steroid-independent and transfusion-dependent </plain></SENT>
<SENT sid="5" pm="."><plain>Baseline clinical or laboratory parameters, in particular in vitro bone marrow erythroid progenitor assays, were not useful in predicting rhIL-3 response </plain></SENT>
<SENT sid="6" pm="."><plain>Two of the responding patients remain on maintenance rhIL-3 without diminution of effect at 490 and 855+ days </plain></SENT>
<SENT sid="7" pm="."><plain>rhIL-3 was discontinued in the other two responders because of the development of deep venous <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
</text></document>